Lifeward (LFWD) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
13 Nov, 2026Executive summary
Q3 revenue fell 12% YoY to $5.428M as lower ReWalk sales outweighed AlterG growth; gross margin declined to 27.4% and net loss widened to $5.052M.
Nine-month revenue was $15.974M, down 6% YoY, while net loss increased to $27.364M; a $4.947M acquired IPR&D charge and financing-related fair-value changes affected results.
AlterG grew double digits as ReWalk sales declined amid the transition from direct sales to channel partners, affecting near-term sales timing.
September 30 cash was $4.548M, and $16.064M of nine-month operating cash outflow contributed to substantial doubt about the ability to continue as a going concern without additional funding or spending cuts.
Financial highlights
Q3 revenue was $5.428M vs. $6.195M YoY; nine-month revenue was $15.974M vs. $16.953M.
Q3 gross profit was $1.487M vs. $2.707M; nine-month gross profit was $5.538M vs. $7.340M.
Q3 operating loss was $5.970M vs. $3.140M; nine-month operating loss was $20.461M vs. $14.556M.
Q3 net loss was $5.052M vs. $3.170M; adjusted net loss was $5.5M. Nine-month net loss was $27.364M vs. $14.566M.
Q3 basic and diluted loss per share was $1.32 vs. $2.37; nine-month loss per share was $9.91 vs. $13.87.
Outlook and guidance
Existing cash resources are not expected to fund planned operations for the next 12 months; potential responses include additional debt or equity, strategic arrangements and cost reductions.
If financing is unavailable, planned liquidity measures include prioritizing R&D, delaying some product development and cutting discretionary expenses.
Growth priorities include ReWalk reimbursement and channel partnerships, higher AlterG shipments, product improvements, ORMD-0801 clinical development and Skelable technology development.
Gross profit and margin are expected to improve over time subject to higher volumes, fixed-cost absorption and operational efficiencies; AI-enabled rehabilitation capabilities are also under development.
Latest events from Lifeward
- Proxy seeks approval for director elections, compensation, auditor, and share issuance above Nasdaq cap.LFWD
Proxy filing - Shareholders will vote on director elections, compensation, share issuance, and auditor re-appointment.LFWD
Proxy filing - Scaling robotics and AI-powered rehab with strong reimbursement and global reach.LFWD
Investor presentation - Q2 2026 revenue up 16% to $6.6M; net loss widens; cash position improves but risks remain.LFWD
Q2 2026 - Registering 2,066,662 shares for resale, with proceeds possible only from warrant exercises.LFWD
Registration filing - Revenue dropped 22% to $3.9M; net loss widened, but cash rose to $11.4M.LFWD
Q1 2026 - Registering 7.26M shares for resale after acquisitions, with no proceeds to the company.LFWD
Registration filing - 2025 revenue fell 14%, but unit sales, gross margin, and efficiency improved amid strategic expansion.LFWD
Q4 2025 - Shareholders to vote on acquisition, major share issuances, and board changes, enabling new growth.LFWD
Proxy Filing